DUBLIN, Die 26 Iunii 2023- Report "Peptide Veneni Market - Global et Regionalis Analysis: Focus in Peptide Genera, Producta et Regionalis Analysis - Analysis et Praedictio, 2024-2040″.
Post primum mercatum deducunt primum medicamentum peptidis restricti, mercatus globalis restrictus praedicatur ab 2024 ad 2040 crescere. Magnitudo mercatus expectatur ad $60M in 2024 et $17.38B in 2040 pervenire, cum CAGR 38,94% super praesagio tempus 2025-2040.
Mercatum pharmacum peptidum restrictum globalis expectat incrementum ingentis incrementi experiri per tempus praesagio ab 2025 ad 2040, magna ex parte acti promissione novi rupturae piperis restricti peptidis, quod non amplius limitatur ad scuta receptoris.Progressus in technologia chemica, in mercatura synthetica peptide therapeutica proximis annis progreditur, et pretia parabilis his biomoleculis in variis morbis effecta quaedam additamenta ad augmentum projecti temporis praesagio conferunt.
Analysis brevis-terminus et diuturnus impactus exercetur in factoribus quae significanter mercatum afficiunt, nempe coegi, angustias et opportunitates.Taxatio breve tempus periodum 2020-2025 considerat et aestimationem longi temporis considerat tempus 2026-2040.
Explicationes et consilia keys a nonnullis clavium histrionum in hoc foro adhibitis in analysi aestimationem impulsum sunt comprehensae.Praeterea hae explicationes praecipuae aestimantur ad intellegendas futuras opportunitates ad integrandas technologias provectas ad superiores eventus consequendos.Praeterea approbationes et excussiones societatum et institutionum patentium etiam ratio habenda est cum aestimandis dynamicis mercati globalis pro medicamentis peptide restricto.
Factores postulatis et angustiis Hae sunt causae postulationis inhibitores mercatus globalis Peptide Dependentia:
4 Market Overview 4.1 Introductio 4.1.1 Structurae et Designatio Restrictae Peptidum 4.1.2 Genera Restrictae Peptidum 4.2 Evolutionis Restrictae Peptidum 4.3 Progressio Restrictae Peptidum Ut Medicamenta 4.4 Potential Areas Therapeutica 4.5 Vinculum valorem - Clavis Stakeholders 4.6 Clavis Industry Trends (per Regio ) ) 4.7 Clavis industriae trends per viam introductionis 4.8 Clavis industriae trends - progressus technologicus 4.9 Current forum amplitudo et incrementum potentiae, USD billion, 2024-2040 et renovatio pro societatibus quae gignunt usum medicamentorum peptidum restrictum
5 Proprietates conformationis restrictae peptidum 5.1 Proprietates conformationis restrictae peptidum 5.2 Synthesis peptidum restrictorum 5.2.1 Ligamentum chemicum peptidum et bridging 5.2.2 Ligamentum chemicum peptidum ad scaffolds (CLIPS) 5.2.3 transmissio peptidum 5.2.4 rostra pro peptide Inventio (5.2.5 Liquid-Phase Peptide Synthesis (LPPS) 5.2.6 Solidum-Phase Peptide Synthesis (SPPS) 5.3 Progressus in Peptide Technologia 5.3.1 Peptide Synthesis Microfluidica 5.3.2 Solidum-Phase Peptide Synthesis Using Proins 5.4 Peptide Propono et Ratio Select
VI Industry Data 6.1 Overview 6.2 Exitus cum Regulatory Approbatio meatus pro Restricted Peptides 6.3 Regulatory missiones pro Restricted Peptides 6.4 US Regulatory Requisita et Structure 6.4.1 Fusce Trial LICENTIA 6.4.2 Venalicium LICENTIA 6.4.3 US FDA Submission DIRECTORIA PRINCIPIA NDA 6.4.4 Post potestatem regulae 6.5 Europaeae legum requisita et compages 6.5.1 EMA licentia applicationis processus 6.5.2 processus centralised 6.5.3 procedendi decentralized 6.5.4 rationes mutuae 6.5.5 rationes nationales 6.6 legum requisita et compages in Asia -Pacific regio 6.6.1 Legum requisita et structura in Iaponia 6.7 Reimbursement missiones 6.7.1 Recompensatio missionum morborum autoimmunerum 6.7.2 Compensatio missionum Cancri 6.7.3 Rara recompensatio missionum morborum
7 Market Edidit 7.1 Impact Analysis 7.2 Fori Factores 7.2.1 Vincula Affinitatis Aucta et Uptake Cellular 7.2.2 Synthetica progressio limitata 7.2.3 Limitationes Conventionis Peptides 7.2.4 Increase in Publica et Privata Sumptu 7.2.4.1 Sumptu privatorum Comitatuum 7.2 .4 .2 Funding recensentur societates 7.2.4.3 Funding institutis publicis 7.3 Coactus mercatus 7.3.1 Certamen biologicum augens 7.3.2 Periculum effectuum immunogenicorum et sub-optimarum proprietatum ADME 7.4 Occasiones mercatus 7.4.1 Peptides limitatae in medicamento inventionis 7.4.2 Variis applicationibus systematis nervosi et cancer justo
8 Quisque landscape 8.1 Overview de landscape competitive 8.1.1 Clavis progressionum 8.1.2 Regulae et actiones legales 8.1.3 Fusiones et acquisitiones 8.1.4 Synergia actiones 8.1.5 Financial operationes 8.1.6 Orci evolutionis
9 Mercatus globalis medicinae coercendi peptide (per directiones), mln USD, 2024-2040 9.1 Fuscus Trial Design pro temperando Peptide Therapies 9.1.1 Potential Phase II Therapiae II) 9.1.2.3 Efficacia, Salus, et Tolerabilitas Data (Scaena 1) 9.1. .2.4 Nonclinical Studies of BT5528 9.1.3 PN-9439.1.3.1 Product Introduction 9.1.3.2 Detentio studiorum (Phase 2) 9.1.3.3 Efficacia, salus et tolerabilitas data (Phase II) 9.1.4 PN-2359.1.4.1 Product introduction 9.1. 4.2 Study design (Phase IIb) 9.1.4.3 Virtus, salus, et tolerabilitas data (Phase IIb) 9.1.5 Rusfertide (PTG-300) 9.1.5.1 Product overview 9.1.5.2 Studio design (Phase II) 9.1.5.3 Efficacia, salus et tolerabilitas data (Phase IIa) 9.1.6 Potential Phase III medicinae 9.1.7 Zilukoplan (RA101495) 9.1.7.1 Product overview 9.1.7.2 Studium design (Phase III) 9.1.7.3 Virtus, salus et tolerabilitas data (Phase III) 9.1.7.4 Pharmacokinetica et pharmacodynamica profile Zilucoplan (Phase I) 9.1.8 Rusfertide (PTG- 300) 9.1.8.1 Product overview 9.1.8.2 De ratione studii (Phase III) 9.1.8.3 Efficacia, salus et tolerabilitas data (Phase II) 9.2 Analysis of the dynamica progressionis mercati globalis pro restrictis medicamentis peptide, USD decies, 2024-2040 successus 9.2.2.2 Custus productionis API (CDMO)
10 Mercatus globalis medicamentorum cum actione peptide limitata (per genus peptide), US$ mln, 2024-2040 peptidium coniunctum (DRP))
11 Mercatus globalis medicinae peptide (per productos potentiales), mln USD, 2024-2040 (RA101495) 11.1.2.1 API productio (domestica) 11.1.2.2 API praecognoscendum postulant 2024-2040 11.1.3 Rusfertide (PTG-300) 11.1 .3.1 API Productio (Outsourcing) Pretium 11.1.4 PN-94311.1.4.1 API Productio (Outsourcing) 11.1.4.2 API Demand Praedictio 2024-2040
Post tempus: Iul-06-2023